13F Holdings
中文EN

AMPH Amphastar Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1297184 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.1%
TTM net income YoY-11.3%
TTM EPS YoY-3.5%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR-9.9%

Margins

Gross margin46.8%
Operating margin18.7%
Net margin13.3%
FCF margin18.6%
EBITDA margin22.4%

Returns

ROE12.4%
ROA5.9%
ROIC (approx.)8.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets52.4%
Debt / equity0.75x
Current ratio3.32x
Interest coverage5.25x

Cash quality & payout

Operating cash flow / net income1.77x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$719.89M$731.97M$644.39M$498.99M$437.77M
Cost of revenue$363.83M$358.11M$293.27M$250.13M$238.03M
Gross profit$356.06M$373.86M$351.12M$248.86M$199.74M
R&D expense$85.84M$73.91M$73.74M$74.77M$60.93M
SG&A expense$85.92M$56.72M$51.54M$45.06M$51.43M
Operating income$140.40M$205.42M$196.99M$107.50M$69.89M
Interest expense$25.48M$30.34M$27.16M$1.85M$885,000
Pretax income$123.62M$189.76M$171.36M$116.04M$84.14M
Income tax$25.53M$29.67M$31.83M$23.48M$20.63M
Net income$98.09M$159.52M$137.54M$91.39M$62.12M
EBITDA$172.05M$233.67M$222.19M$131.31M$80.11M
EPS (basic)2.103.292.851.881.30
EPS (diluted)2.033.062.601.741.25
Weighted avg. shares (diluted)48.22M52.06M53.00M52.43M49.78M
Balance sheet
Cash & equivalents$170.18M$151.84M$144.53M$156.33M$126.59M
Short-term investments$112.64M$70.04M$112.51M$19.66M$10.32M
Receivables$143.56M$136.29M$114.94M$88.80M$78.80M
Inventory$176.89M$153.74M$105.83M$103.58M$92.81M
Current assets$636.02M$534.07M$489.60M$378.32M$318.12M
PP&E, net$310.57M$297.35M$282.75M$238.27M$244.24M
Goodwill$3.40M$3.05M$3.22M$3.13M$3.31M
Intangibles$533.34M$558.39M$580.85M$4.95M$6.33M
Total assets$1.63B$1.58B$1.51B$741.99M$671.53M
Current liabilities$158.16M$173.76M$225.41M$94.86M$103.81M
Short-term debt$1.64M$234,000$436,000$3.05M$2.20M
Long-term debt$608.75M$601.63M$589.58M$72.84M$74.78M
Total debt$610.39M$601.86M$590.01M$75.89M$76.98M
Total liabilities$840.49M$845.17M$873.49M$213.33M$226.01M
Shareholders' equity$788.80M$732.30M$639.42M$528.66M$445.52M
Net debt$440.21M$450.02M$445.48M-$80.45M-$49.61M
Shares outstanding45.65M47.62M48.07M48.11M47.71M
Cash flow statement
Operating cash flow$156.12M$213.39M$183.50M$89.18M$97.99M
Capital expenditure$34.88M$41.04M$38.17M$24.03M$27.46M
Free cash flow$121.23M$172.34M$145.34M$65.15M$70.54M
Investing cash flow-$70.33M-$124.93M-$649.12M-$32.78M-$28.67M
Financing cash flow-$67.42M-$80.95M$454.09M-$26.44M-$37.02M
Depreciation & amortization$31.65M$28.25M$25.20M$23.82M$10.22M
Stock-based compensation$27.28M$24.37M$20.24M$17.86M$18.69M
Share buybacks$75.59M$85.46M$58.14M$39.91M$28.87M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.